TY - JOUR
AU - He, Rongqiao
AB - SCIENCE CHINA Life Sciences •LETTER TO THE EDITOR• December 2018 Vol.61 No.12: 1596–1598 https://doi.org/10.1007/s11427-018-9441-9 Yuan Zhou, Xiumei Wang, Shichao Fan & Rongqiao He Institute of Biophysics, University of Chinese Academy of Sciences, Beijing 100101, China Received November 20, 2018; accepted November 27, 2018; published online December 3, 2018 Citation: Zhou, Y., Wang, X., Fan, S., and He, R. (2018). A lumbrokinase isozyme targets hepatitis B e-antigen. Sci China Life Sci 61, 1596–1598. https://doi. org/10.1007/s11427-018-9441-9 Dear Editor, fibrinolytic activity (Nakajima et al., 2003). The group of isozymes has been made into an enteric-coated capsule in the Hepatitis B Virus (HBV) infection remains a major health treatment of stroke over 20years. Here we show that one of problem worldwide despite the availability of a highly ef- the isozymes from E. fetida is able to recognize and degrade fective preventive vaccine. HBV genome codes several HBeAg, suggesting that lumbrokinase could be used as a distinct proteins, among which the non-particulate e-antigen potentialdrugtotargetHBeAginthetreatmentofhepatitisB. (HBeAg) is one of the important markers in HBVinfection. The isozymes of lumbrokinase were prepared by an ionic Sera containing HBeAg are highly infectious but those with columnfollowedbyaffinitychromatographywithagradient anti-HBeAg have little infectivity. The spontaneous or GuHCl (Figure S1A). The purified 
TI - A lumbrokinase isozyme targets hepatitis B e-antigen
JF - "Science China Life Sciences"
DO - 10.1007/s11427-018-9441-9
DA - 2018-12-01
UR - https://www.deepdyve.com/lp/springer-journals/a-lumbrokinase-isozyme-targets-hepatitis-b-e-antigen-79NvnN1ntE
SP - 1596
EP - 1598
VL - 61
IS - 12
DP - DeepDyve
ER -